Guarini et al. demonstrated that CD19-directed CAR T cell treatment of DLBCL and ALL patients induces a reshaping of the immune system by increasing T cell counts and inducing cytokine production [20]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.